Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its earnings results on Tuesday. The company reported ($0.83) earnings per share for the quarter, hitting the consensus estimate of ($0.83), Bloomberg Earnings reports. The business had revenue of $4.91 million for the quarter. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%.

Neos Therapeutics (NASDAQ:NEOS) traded down 2.14% on Wednesday, reaching $6.85. The company’s stock had a trading volume of 393,057 shares. The company’s market capitalization is $154.54 million. Neos Therapeutics has a 1-year low of $4.85 and a 1-year high of $9.60. The stock has a 50 day moving average price of $7.12 and a 200-day moving average price of $6.93.

NEOS has been the topic of several research reports. ValuEngine raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 18th. Zacks Investment Research lowered Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, Cantor Fitzgerald initiated coverage on Neos Therapeutics in a research report on Monday, July 31st. They issued an “overweight” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Neos Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $14.00.

COPYRIGHT VIOLATION WARNING: “Neos Therapeutics, Inc. (NASDAQ:NEOS) Posts Quarterly Earnings Results, Meets Estimates” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Earnings History for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.